Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT04635059
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pacritinib — DRUG
    Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).

Study Details

This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.

Key Dates

Start date
Jun 1, 2021
Status verified
Oct 2025
Primary completion
Nov 30, 2023
Completion
Oct 27, 2024

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pacritinib
    Pacritinib is an oral drug.

Primary Outcome Measure

The Number of Patients With Six-month PSA Progression-free Survival. [ Time Frame: Six months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Froedtert & the Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Milwaukee, WI

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Froedtert & the Medical College of Wisconsin· Milwaukee, WI

Related Studies